genentech inc suffering only temporary setback following agency decision withhold recommendation its genetically produced drug which used treat heart attacks progress industry sources and analysts said when tpa drug first came scene projected time scale for approval was 1990 said milstein scientist and industry consultant even with new delay has arisen all likelihood drug will approved prior initial projections added last friday advisory committee food and drug administration fda withheld recommendation genentech tissue plasminogen activator drug called activase athough supported genentech claim drug dissolves blood clots fda said wanted data showed treatment benefits heart attack victims will talking fda soon possible ask specifically looking for genentech spokeswoman said said company had data showed improvement heart muscle after drug was administered but had not included fda filing industry analysts also said point drop company stock was largely expected light speculative nature biotechnology companies whose fortunes often depend success important drug larger pharmaceutical companies each product does not have much overall significance but this very important genentech said robert riley senior consultant arthur little inc some estimated genentech could much billion dlrs from drug but with each delay others can enter market and catch genentech lead industry sources pointed out kabivitrum alliance with hoechst won recommendation for its streptokinase drug same day genentech application was delayed streptokinase enzyme based drug also used treat heart attack victims addition milstein said beecham group plc has drug called eminase which most likely competitor tpa and from clinical standpoint nearly identical beecham drug has been approved for germany and awaiting approval added streptokinase was difficult administer heart attack victims because would dissolve before reached heart another method which involved pumping drug directly into heart through tube proved difficult when heart attack was progress tpa was seen savior since was easier administer and worked quickly but new developments have made streptokinase more effective and easier administer becoming potential threat genentech grasp tpa market and wasn enough about biotech companies quickly developing tpa genentech path genentech advantage being first market said industry consultant scott king formerly analyst with montgomery securities san francisco first approved but then face competition after two years company may also face patent pressures for its drug currently about court with beecham group patent dispute and while its patent pending many analysts expect company face some suits soon patent issued potentially more harmful situation any temporary setback fda reuter 